Scienture Holdings, Inc.
SCNXHealthcare|Medical - Pharmaceuticals|US
$3.13
+0.03 (+0.81%)
DCF Value
$1.00
Cash / Share
$5.17
Financials
Financial Snapshot
Market Cap
$5.1M
Enterprise Value
$7.6M
Revenue (TTM)
$821.3K
Net Income (TTM)
-$38.0M
Cash & Investments
$8.2M
Net Cash
-$2.5M
Free Cash Flow (TTM)
-$14.4M
Operating CF (TTM)
-$14.4M
Debt/Equity
0.17
Cash Runway & Burn Rate
Cash on Hand
$8.2M
Quarterly Burn
$3.6M
Monthly Burn
$1.2M
Est. Runway
~2.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $14.7K | $183.9K | $869.6K | $2.9M | $5.9M | $3.1M | $1.1M | $314.00 | $308.1K | $6.7M | $8.2M | |
| Operating Cash Flow | -$1.3M | $171.7K | $273.4K | $141.8K | -$2.2M | -$2.6M | -$1.6M | -$2.2M | -$14.3M | -$13.4M | -$14.4M | |
| Free Cash Flow | -$1.3M | $171.7K | $258.4K | $59.5K | -$2.3M | -$2.6M | -$1.6M | -$2.2M | -$14.3M | -$13.4M | -$14.4M | |
| Capital Expenditure | $0.00 | $0.00 | -$15.0K | -$82.3K | -$37.5K | -$22.6K | $0.00 | $0.00 | -$12.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $1.2M | -$2.4K | $677.5K | $2.2M | $5.3M | -$208.2K | -$35.2K | $1.4M | -$13.0M | $19.7M | $25.6M |
R&D Spending
R&D (TTM)
$2.5M
R&D Intensity
304.2%
R&D Growth vs Prior
+27.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.9M | $3.8M | $7.4M | $17.1M | $9.9M | $10.3M | $1.4M | $136.6K | $431.6K | $821.3K | |
| R&D Expense | $0.00 | $863.3K | $949.9K | $0.00 | $662.7K | $899.7K | $993.2K | $100.3K | $2.2M | $2.0M | $2.5M | |
| R&D % of Revenue | 0.0% | 29.5% | 24.8% | 0.0% | 3.9% | 9.1% | 9.7% | 7.4% | 1636.9% | 453.3% | 304.2% | |
| SG&A | $3.3M | $1.4M | $3.5M | $4.4M | $7.5M | $7.5M | $6.6M | $4.4M | $12.1M | $14.5M | $2.02B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.9M | $3.8M | $7.4M | $17.1M | $9.9M | $10.3M | $1.4M | $136.6K | $431.6K | $821.3K | |
| Cost of Revenue | $16.4K | $0.00 | $449.0K | $2.6M | $11.4M | $5.1M | $4.7M | $1.3M | $130.6K | $100.1K | $568.9K | |
| Gross Profit | $2.5M | $2.9M | $3.4M | $4.9M | $5.7M | $4.7M | $5.5M | $49.0K | $6.0K | $331.5K | $252.4K | |
| R&D | $0.00 | $863.3K | $949.9K | $0.00 | $662.7K | $899.7K | $993.2K | $100.3K | $2.2M | $2.0M | $2.5M | |
| SG&A | $3.3M | $1.4M | $3.5M | $4.4M | $7.5M | $7.5M | $6.6M | $4.4M | $12.1M | $14.5M | $2.02B | |
| Operating Income | -$1.0M | $395.1K | -$87.6K | $125.2K | -$2.5M | -$5.3M | -$2.9M | -$4.4M | -$14.7M | -$16.2M | -$13.7M | |
| Interest Expense | $151.5K | $157.1K | $57.5K | $53.2K | $29.4K | $23.6K | $336.2K | $1.1M | $1.3M | $4.1M | $3.1M | |
| Pretax Income | -$1.2M | $289.0K | $9.0K | -$284.4K | -$2.5M | -$5.3M | -$2.4M | -$8.5M | -$18.8M | -$43.5M | -$39.9M | |
| Net Income | -$2.8M | $289.0K | $9.0K | -$284.4K | -$2.5M | -$5.3M | -$3.5M | -$17.8M | $9.1M | -$41.5M | -$38.0M | |
| EPS (Diluted) | -196.75 | 22.50 | 0.58 | -18.00 | -123.50 | -245.00 | -153.75 | -187.25 | 62.00 | -67.50 | -51.00 | |
| EBITDA | -$1.0M | $446.0K | $66.6K | -$136.5K | -$2.4M | -$5.2M | -$1.9M | -$6.3M | -$17.4M | -$38.9M | -$35.6M | |
| Shares Out. (M) | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.10 | 0.15 | 6.14 | 1.58 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.7K | $183.9K | $869.6K | $2.9M | $5.9M | $3.1M | $1.1M | $314.00 | $308.1K | $6.7M | $8.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $337.1K | $607.5K | $1.5M | $3.8M | $9.2M | $4.4M | $2.1M | $2.8M | $6.3M | $7.9M | $9.2M | |
| Total Assets | $337.1K | $617.5K | $2.2M | $5.6M | $9.8M | $5.8M | $3.7M | $12.5M | $104.9M | $84.2M | $87.7M | |
| Total Current Liabilities | $1.5M | $525.4K | $860.4K | $520.8K | $842.2K | $926.0K | $2.1M | $11.6M | $7.9M | $2.7M | $3.0M | |
| Long-Term Debt | $10.6K | $404.1K | $522.6K | $225.0K | $0.00 | $0.00 | $333.3K | $25.0K | $612.3K | $0.00 | $9.6M | |
| Total Liabilities | $1.5M | $929.4K | $1.4M | $1.4M | $1.1M | $2.0M | $3.4M | $12.0M | $25.8M | $14.1M | $23.6M | |
| Stockholders' Equity | -$1.1M | -$311.9K | $844.7K | $4.1M | $8.7M | $3.8M | $763.1K | $542.4K | $79.1M | $70.1M | $64.1M | |
| Retained Earnings | -$8.4M | -$8.1M | -$8.1M | -$8.4M | -$10.9M | -$16.2M | -$19.7M | -$33.2M | -$39.0M | -$80.6M | -$86.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M | $171.7K | $273.4K | $141.8K | -$2.2M | -$2.6M | -$1.6M | -$2.2M | -$14.3M | -$13.4M | -$14.4M | |
| Capital Expenditure | $0.00 | $0.00 | -$15.0K | -$82.3K | -$37.5K | -$22.6K | $0.00 | $0.00 | -$12.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$1.3M | $171.7K | $258.4K | $59.5K | -$2.3M | -$2.6M | -$1.6M | -$2.2M | -$14.3M | -$13.4M | -$14.4M | |
| Investing Cash Flow | -$78.0K | $0.00 | -$265.3K | -$332.3K | -$37.5K | -$22.6K | -$427.8K | -$275.7K | $27.6M | $0.00 | $0.00 | |
| Financing Cash Flow | $1.2M | -$2.4K | $677.5K | $2.2M | $5.3M | -$208.2K | -$35.2K | $1.4M | -$13.0M | $19.7M | $25.6M | |
| Issuance of Stock | $300.0K | $250.0K | $800.0K | $2.5M | $6.0M | $0.00 | $131.8K | $518.0K | $26.4K | $26.3M | $32.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $321.1K | -$252.7K | -$122.5K | -$262.6K | $0.00 | -$225.0K | $0.00 | $250.0K | $3.1M | -$6.2M | -$6.3M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $1.4M | $181.2K | $254.1K | $257.8K | $0.00 | $2.1M | $248.5K | |
| Net Change in Cash | -$64.0K | $169.2K | $685.6K | $2.0M | $3.0M | -$2.8M | -$2.0M | -$1.1M | $307.8K | $6.4M | $8.2M |
Dilution Tracker
Shares outstanding grew 29776.0% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+29776.0%
Stock Issuance (TTM)
$32.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.10 | 0.15 | 6.14 | 1.58 | |
| Change vs Prior % | — | 8.1% | 2.5% | 1.8% | 30.0% | 5.6% | 4.1% | 321.6% | 53.4% | 4100.6% | -74.2% | |
| Stock Issuance | $300.0K | $250.0K | $800.0K | $2.5M | $6.0M | $0.00 | $131.8K | $518.0K | $26.4K | $26.3M | $32.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $1.4M | $181.2K | $254.1K | $257.8K | $0.00 | $2.1M | $248.5K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 99.3% | 100.0% | 88.3% | 65.5% | 33.3% | 48.0% | 53.8% | 3.6% | 4.4% | 76.8% | 30.7% | |
| Operating Margin % | -40.6% | 13.5% | -2.3% | 1.7% | -14.6% | -53.5% | -28.4% | -322.4% | -10758.7% | -3763.8% | -1671.1% | |
| Net Margin % | -111.2% | 9.9% | 0.2% | -3.8% | -14.8% | -53.8% | -33.9% | -1308.3% | 6634.7% | -9618.0% | -4620.9% | |
| EBITDA Margin % | -41.2% | 15.2% | 1.7% | -1.8% | -14.0% | -52.1% | -18.3% | -461.2% | -12726.5% | -9020.2% | -4339.1% | |
| FCF Margin % | -52.9% | 5.9% | 6.7% | 0.8% | -13.2% | -26.2% | -15.3% | -163.2% | -10448.6% | -3100.0% | -1758.2% | |
| ROE % | 240.4% | -92.6% | 1.1% | -6.9% | -29.2% | -141.0% | -455.0% | -3290.0% | 11.5% | -59.2% | -53.5% | |
| ROA % | -818.7% | 46.8% | 0.4% | -5.1% | -25.9% | -92.2% | -93.6% | -142.4% | 8.6% | -49.3% | -43.3% | |
| ROIC % | 274.7% | 111.5% | -5.2% | 2.4% | -26.9% | -105.5% | -151.3% | -58.3% | -14.3% | -19.0% | -15.2% | |
| R&D / Revenue % | 0.0% | 29.5% | 24.8% | 0.0% | 3.9% | 9.1% | 9.7% | 7.4% | 1636.9% | 453.3% | 304.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -14.8% | 18.1% | 30.7% | 94.1% | 130.3% | -42.2% | 3.6% | -86.7% | -90.0% | 215.9% | |
| Gross Profit | -9.4% | 18.9% | 15.4% | 44.0% | 17.2% | -16.8% | 16.3% | -99.1% | -87.8% | 5420.1% | |
| Operating Income | -634.9% | 139.2% | -122.2% | 242.9% | -2101.7% | -111.1% | 44.9% | -50.8% | -234.4% | -10.5% | |
| Net Income | -147.1% | 110.5% | -96.9% | -3247.0% | -791.6% | -109.6% | 34.7% | -413.9% | 150.8% | -557.9% | |
| EPS (Diluted) | -145.2% | 111.4% | -97.4% | -3190.1% | -586.1% | -98.4% | 37.2% | -21.8% | 133.1% | -208.9% | |
| Operating Cash Flow | 33.5% | 113.1% | 59.3% | -48.1% | -1662.2% | -15.9% | 39.0% | -42.2% | -541.1% | 6.2% | |
| Free Cash Flow | 33.5% | 113.1% | 50.5% | -77.0% | -3883.9% | -14.9% | 39.6% | -42.2% | -541.6% | 6.3% | |
| R&D Expense | 0.0% | 0.0% | 10.0% | -100.0% | 0.0% | 35.8% | 10.4% | -89.9% | 2130.4% | -12.5% | |
| SG&A Expense | 16.8% | -58.0% | 147.0% | 26.1% | 71.1% | 0.6% | -12.9% | -32.3% | 171.2% | 20.5% | |
| Total Assets | -83.4% | 83.2% | 260.8% | 150.1% | 75.8% | -41.1% | -35.7% | 237.8% | 736.6% | -19.7% | |
| Book Value / Share | -526.8% | 73.2% | 368.3% | 344.4% | 61.3% | -58.9% | -91.3% | 16.9% | 3200.3% | -98.0% | |
| Debt | -29.5% | -14.7% | 26.7% | 18.2% | -37.1% | 99.0% | 26.9% | 327.1% | -47.8% | -99.3% | |
| Diluted Shares | 0.7% | 8.1% | 2.5% | 1.8% | 30.0% | 5.6% | 4.1% | 321.6% | 53.4% | 4100.6% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High2.25 / 8.32 / 297.22
P/S6.25
10Y Low / Med / High0.22 / 0.91 / 181.35
P/B0.08
10Y Low / Med / High0.26 / 1.12 / 10.55
EV/EBITDAAt Loss
10Y Low / Med / High0.60 / 7.04 / 39.93
EV/Revenue9.30
10Y Low / Med / High0.15 / 1.07 / 173.04
P/FCFAt Loss
10Y Low / Med / High10.39 / 15.49 / 49.74
Intrinsic Value Models (per share)
DCF Value
$1.00
Cash / Share
$5.17
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.95 | 8.32 | 297.22 | -10.40 | -1.52 | -0.76 | -1.22 | -0.32 | 2.25 | -0.19 | -0.07 | |
| P/S Ratio | 1.06 | 0.91 | 0.70 | 0.40 | 0.22 | 0.41 | 0.41 | 4.20 | 149.45 | 181.35 | 6.25 | |
| P/B Ratio | -2.29 | -8.53 | 3.18 | 0.72 | 0.44 | 1.08 | 5.54 | 10.55 | 0.26 | 1.12 | 0.08 | |
| EV/EBITDA | -3.32 | 7.04 | 39.93 | -7.96 | 0.60 | -0.42 | -2.52 | -1.99 | -1.36 | -1.84 | -0.21 | |
| EV/Revenue | 1.37 | 1.07 | 0.69 | 0.15 | -0.08 | 0.22 | 0.46 | 9.16 | 173.04 | 165.97 | 9.30 |
Analyst Estimates & Quality
Altman Z-Score
-2.55
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.6M | $15.5M | $35.2M |
| Net Income | -$27.3M | -$1.7M | $6.7M |
| EPS | $-4.44 | $-0.27 | $1.09 |
| # Analysts (EPS) | 1 | 1 | 1 |
Dividends
Frequency
Special
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Jul 19, 2024 | Jul 24, 2024 | $1.50 | Special |
| Mar 25, 2024 | $8.00 | Special |
Revenue Segments
By Geography
| Segment | 2024 |
|---|---|
| UNITED STATES | $136.6K |